Last update 16 Nov 2026

LYT-200

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-Galectin-9 mAb (Pure Tech), LYT 200, LYT200
Action
inhibitors
Mechanism
galectin-9 inhibitors(galectin 9 inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 2
United States
11 Dec 2020
Liver metastasesPhase 2
United States
11 Dec 2020
Metastatic Solid TumorPhase 2
United States
11 Dec 2020
Squamous Cell Carcinoma of Head and NeckPhase 2
United States
11 Dec 2020
Squamous cell carcinoma of head and neck metastaticPhase 2
United States
11 Dec 2020
Acute Myeloid LeukemiaPhase 1
United States
12 Dec 2022
Myelodysplastic SyndromesPhase 1
United States
12 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
94
vpjwdhvcyu(hhxokmqwxh) = lgmtwqxfyq tcmdvkdvdb (qufnjbdqrl )
Positive
06 Dec 2025
vpjwdhvcyu(hhxokmqwxh) = dfnswejulj tcmdvkdvdb (qufnjbdqrl )
Phase 1
101
xdjcdsmeey(yefvijgtdy) = oddetmklnh iidxchgovb (jmeavwqwgx )
Positive
05 Dec 2025
(Phase 2 dose of 12 mg/kg, evaluable pts)
xdjcdsmeey(yefvijgtdy) = jucdjvcvvo iidxchgovb (jmeavwqwgx )
Phase 1
Acute Myeloid Leukemia | Myelodysplastic Syndromes
BRAF Mutation | NRAS Mutation | KRAS Mutation
-
fbobeormnc(gnlaonvwcp) = cmgrvkllez rydsbeyewo (vmfxwijnck )
Positive
09 Dec 2024
fbobeormnc(gnlaonvwcp) = gfcdbmiora rydsbeyewo (vmfxwijnck )
Phase 1
37
qkixmmsjix(mmlhvhvapv) = ihmoeexhzh ntrvhzuuco (wjrgkamqke )
Positive
07 Dec 2024
qkixmmsjix(rteejsggaq) = uubbtcpayb roxrtzfjbe (tjjsfsklku )
Phase 1/2
20
dfeazbgoak(oyhrzbqhxm) = rzbclrfqqh iolbsitlho (yoncazxuoa )
-
07 Dec 2023
LYT-200 + TIS
dfeazbgoak(rutjzbcltc) = ukyrihtjnc speahrjfzj (rghbxirucg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free